Examkin

Question

Difficulty: HardInfectious Diseases

A 68-year-old man is evaluated in the intensive care unit for worsening oxygenation and a new-onset fever. He was admitted 8 days ago for severe acute respiratory distress syndrome secondary to influenza A, requiring endotracheal intubation and mechanical ventilation. Over the past 48 hours, his fraction of inspired oxygen (FiO2) requirement has increased from 40% to 60%. His temperature is 39.1°C (102.4°F), blood pressure is 110/65 mm Hg, and pulse is 108/min. Physical examination reveals coarse rhonchi bilaterally and copious, purulent secretions from the endotracheal tube. A chest radiograph demonstrates a new consolidation in the left lower lobe. Endotracheal aspirate and blood cultures are obtained. The patient is empirically started on intravenous piperacillin-tazobactam, vancomycin, and amikacin. Three days later, his clinical condition has significantly improved, and his oxygen requirements have decreased. The endotracheal aspirate culture yields heavy growth of Pseudomonas aeruginosa. Susceptibility testing indicates the isolate is sensitive to piperacillin-tazobactam, ceftazidime, cefepime, and ciprofloxacin, but resistant to amikacin. Blood cultures show no growth after 72 hours. Which of the following is the most appropriate next step in pharmacotherapy?

  1. A
    Discontinue the current regimen and initiate therapy with intravenous ceftazidime and ciprofloxacin
  2. Discontinue vancomycin and amikacin, and continue piperacillin-tazobactam monotherapyAnswer
  3. C
    Discontinue amikacin, and continue piperacillin-tazobactam and vancomycin
  4. D
    Continue the current empiric regimen of piperacillin-tazobactam, vancomycin, and amikacin
  5. E
    Discontinue vancomycin, and continue piperacillin-tazobactam and amikacin

Answer

Discontinue vancomycin and amikacin, and continue piperacillin-tazobactam monotherapy
The core principle of antimicrobial stewardship in the intensive care unit is de-escalation. The patient's empiric regimen appropriately covered methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Once endotracheal aspirate cultures identified only Pseudomonas aeruginosa susceptible to piperacillin-tazobactam, MRSA coverage (vancomycin) must be discontinued. For definitive treatment of ventilator-associated pneumonia caused by Pseudomonas, a single active beta-lactam agent (in this case, piperacillin-tazobactam) is recommended. The addition of a second agent (such as an aminoglycoside or fluoroquinolone) is not indicated for definitive therapy unless the isolate is highly resistant to beta-lactams, and in this specific scenario, the isolate is resistant to the empirically chosen aminoglycoside anyway.

Step-by-Step Solution

1
Identify the clinical condition based on the presentation.
The patient developed a new fever, increased oxygen requirements, purulent secretions, and a new pulmonary infiltrate 8 days after intubation, consistent with a diagnosis of ventilator-associated pneumonia (VAP).
Establishing the diagnosis determines the required initial empiric antibiotic spectrum.
2
Evaluate the initial empiric therapy.
Empiric coverage appropriately included agents targeting MRSA (vancomycin) and providing double coverage for Pseudomonas aeruginosa (piperacillin-tazobactam and amikacin) given the patient's risk factors.
Current guidelines recommend broad initial coverage for VAP until causative organisms are identified.
3
Analyze the lower respiratory tract culture and susceptibility data.
The culture confirms Pseudomonas aeruginosa that is sensitive to piperacillin-tazobactam but resistant to amikacin. No MRSA was isolated.
Definitive therapy must be tailored based on microbiologic data to ensure efficacy and minimize toxicity.
4
Apply antimicrobial stewardship principles to modify the regimen.
Discontinue vancomycin (no MRSA isolated) and discontinue amikacin (isolate is resistant). Continue piperacillin-tazobactam as monotherapy.
For definitive treatment of VAP caused by Pseudomonas aeruginosa, de-escalation to a single active beta-lactam agent is standard practice. Double coverage is not routinely recommended for definitive therapy.

Key Concept

De-escalation of empiric broad-spectrum antibiotics to targeted monotherapy in ventilator-associated pneumonia once culture and susceptibility data are available.
Rate this question

Topics

Infectious Diseases

More questions from this topic